Antibody- and Radionuclide Drug Conjugates: Advanced vial solutions for cutting-edge cancer treatments

Latest innovations in drug technologies seek to bring cancer treatment to the next level. For example, using the targeting ability of monoclonal antibodies in combination with a cytotoxic (Antibody Drug Conjugates) or radioactive molecule (Radionucleotide Drug Conjugates). These medicines offer a promising alternative to common radiation or chemotherapy, potentially increasing effectiveness and reducing side effects for patients due to their precision.

However, these drugs have complex structures that pose certain challenges in processing and storage in primary packaging. Stability issues often necessitate lyophilization, while liquid formulations can be affected by glass leachables. Additionally, light sensitivity may present further hurdles. Join this Pharmaversity® session and learn what vial solutions SCHOTT Pharma offers to address these challenges.